Axiom Biosciences reported early-phase positive results for a mesenchymal stem cell therapy in newborns with severe brain injury, with plans to expand development into ischemic stroke. The news forms part of BioCentury’s Clinical Report coverage, highlighting how the company is testing stem-cell approaches in neonatal neurological conditions tied to high mortality and long-term disability. The therapy is co-developed with South Korea-based Medinno Inc. and targets intraventricular hemorrhage (IVH) and hypoxic-ischemic encephalopathy (HIE). Separately, the same report noted GSK discontinued development of a P2X3 receptor antagonist for refractory chronic cough, underscoring ongoing attrition in target-based neurology programs. While detailed efficacy and dosing specifics were not included in the excerpt, the readout is positioned as an early validation step for the stem-cell program and a rationale for moving the strategy toward additional indications in the neuro pipeline.